Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to

smear
levofloxacin
clofazimine
pyrazinamide
linezolid
  • 0 views
  • 24 Jan, 2021
  • 13 locations
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA

  • 0 views
  • 29 Jan, 2021
  • 13 locations
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the overall treatment success rate of MDR-TB is 55% …

isoniazid
sputum culture
chest x-ray
rifampin
extensively drug-resistant tuberculosis
  • 0 views
  • 23 Jan, 2021
  • 20 locations
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

moxifloxacin
bedaquiline
clofazimine
pretomanid
linezolid
  • 0 views
  • 16 May, 2021
  • 6 locations
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

bedaquiline
clofazimine
vasectomy
linezolid pill
linezolid
  • 94 views
  • 25 Jan, 2021
  • 6 locations
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD

pulmonary disease
clofazimine
  • 702 views
  • 15 May, 2021
  • 7 locations
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

To conduct an open-label randomized controlled trial on a short course of interferon -1b and clofazimine combination treatment for patients hospitalized for COVID-19 infection. To assess its

interferon
SARS
covid-19
critical illness
  • 30 views
  • 25 Jan, 2021
  • 1 location
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline Delamanid and Linezolid) With the Current South African Standard of Care

of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) and clofazimine (CFZ) compared to the current South African Standard of Care (Control Strategy) for 9 months for

isoniazid
bedaquiline
clofazimine
susceptibility testing
linezolid oral tablet
  • 0 views
  • 24 Jan, 2021
  • 1 location
Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

This study is a randomized, controlled, multi-center clinical study. The main purpose of this study was to study the efficacy and safety data of total oral short-term therapy as an alternative to injection in the treatment of newly diagnosed RR-TB patients.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis

PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations

bedaquiline
clofazimine
pyrazinamide
linezolid
moxifloxacin
  • 0 views
  • 12 May, 2021
  • 4 locations